About this trial
To evaluate the correlation between maxLCBI4mm/FCTmin(a new index of lipid plaque based on NIRS-OCT technology) and fiber cap thickness , and the prognosis of patients, providing a new quantitative index for early, accurate and comprehensive identification of vulnerable plaques, and exploring preventive measures for adverse events such as cardiac death and recurrent myocardial infarction caused by vulnerable plaques, so as to improve the long-term prognosis of patients.
Eligibility criteria
Qualifiers
18 years old or older, gender is not limited
Patients with diabetes who require an OCT examination or treatment under OCT guidance (diabetes definition: active treatment with insulin or oral hypoglycemic agents at admission). For patients with diabetes who are treated with diet only, abnormal fasting blood sugar (>7 mmol/l), blood sugar >11.1 mmol/l at any time, or abnormal glucose tolerance tests based on World Health Organization standards need to be recorded.
Be able to understand the purpose of clinical research, voluntarily participate can complete the observation as required and sign the informed consent form
Disqualifiers
1: Severe coagulation dysfunction (APTT greater than 3 times the upper limit of the normal range)
Trial design
Treatments tested in this trial
- Not listed